Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Nuvectis Pharma (NVCT)
NASDAQ:NVCT
Nuvectis Pharma (NVCT) Stock Price & Analysis
46 Followers
NVCT Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$6.20 - $18.65
Previous Close$6.82
Volume44.46K
Average Volume (3M)101.77K
Market Cap
$119.41M
Enterprise Value$100.31M
Total Cash (Recent Filing)$19.10M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)-4.9
Beta0.62
Next Earnings
May 08, 2024EPS Estimate
-$0.4Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.40
Shares Outstanding17,768,824
10 Day Avg. Volume56,913
30 Day Avg. Volume101,770
Standard Deviation0.21
R-Squared0.00513
Alpha0.02
Financial Highlights & Ratios
Price to Book (P/B)9.84
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-7.80
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-28.70
Enterprise Value/Ebitda-5.99
Forecast
1Y Price Target
$21.00Price Target Upside207.92% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
Nuvectis Pharma News
Ownership Overview
50.58% Insiders
2.56% Mutual Funds
4.13% Other Institutional Investors
42.73% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
NVCT FAQ
What was Nuvectis Pharma’s price range in the past 12 months?
Nuvectis Pharma lowest stock price was $6.20 and its highest was $18.65 in the past 12 months.
What is Nuvectis Pharma’s market cap?
Currently, no data Available
When is Nuvectis Pharma’s upcoming earnings report date?
Nuvectis Pharma’s upcoming earnings report date is May 08, 2024 which is in 12 days.
How were Nuvectis Pharma’s earnings last quarter?
Nuvectis Pharma released its earnings results on Mar 05, 2024. The company reported -$0.41 earnings per share for the quarter, the consensus estimate of -$0.41 by $0.
Is Nuvectis Pharma overvalued?
According to Wall Street analysts Nuvectis Pharma’s price is currently Undervalued.
Does Nuvectis Pharma pay dividends?
Nuvectis Pharma does not currently pay dividends.
What is Nuvectis Pharma’s EPS estimate?
Nuvectis Pharma’s EPS estimate is -$0.4.
How many shares outstanding does Nuvectis Pharma have?
Nuvectis Pharma has 17,768,824 shares outstanding.
What happened to Nuvectis Pharma’s price movement after its last earnings report?
Nuvectis Pharma reported an EPS of -$0.41 in its last earnings report, expectations of -$0.41. Following the earnings report the stock price went down -0.971%.
Which hedge fund is a major shareholder of Nuvectis Pharma?
Currently, no hedge funds are holding shares in NVCT
---
Nuvectis Pharma Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$21.00 (207.92% Upside)
$21.00 (207.92% Upside)
Blogger Sentiment
Bullish
NVCT Sentiment 100%
Sector Average 70%
Sector Average 70%
Insider Transactions
Bought Shares
Worth $51.5K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-53.53%
12-Months-Change
Fundamentals
Return on Equity
-168.51%
Trailing 12-Months
Asset Growth
-5.98%
Trailing 12-Months
Company Description
Nuvectis Pharma
Nuvectis Pharma Inc is a biopharmaceutical company. The company is engaged in the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology. Its pipeline products include NXP800, NXP900.
---
NVCT Stock 12 Months Forecast
Average Price Target
$21.00
▲(207.92% Upside)
Technical Analysis
Best Analysts Covering NVCT
1 Year
1 Year Success Rate
1/7 ratings generated profit
1 Year Average Return
-29.71%
reiterated a buy rating 18 days ago
Copying Joseph Pantginis's trades and holding each position for 1 Year would result in 14.29% of your transactions generating a profit, with an average return of -29.71% per trade.
---